id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0082-0005,FDA,FDA-2004-E-0082,Determination of Regulatory Review Period for Purposes of Patent Extension; UROXATRAL,Notice,General Notice,2006-07-25T04:00:00Z,2006,7,2006-06-13T04:00:00Z,,2025-11-18T23:55:43Z,E6-9201,0,0,090000648046edde
FDA-2004-E-0082-0003,FDA,FDA-2004-E-0082,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-18T23:49:14Z,,0,0,090000648046eddb
FDA-2004-E-0082-0004,FDA,FDA-2004-E-0082,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-18T23:51:51Z,,0,0,090000648046eddc